The UK biotech company which co-developed the ChadOx1 vaccine platform used in the Oxford/AstraZenecavaccine is preparing to launch a $100m initial public offering in the US.
The company looks likely to raise that sum when it makes its debut on the NASDAQ exchange in the coming days, but fears about the safety profile of its leading vaccine platform could impact its
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?